ProKidney Corp
NASDAQ:PROK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ProKidney Corp
Selling, General & Administrative
ProKidney Corp
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
ProKidney Corp
NASDAQ:PROK
|
Selling, General & Administrative
-$51.8m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$14B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$5.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$6.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.8B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$3.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-15%
|
|
ProKidney Corp
Glance View
ProKidney Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Winston-Salem, North Carolina and currently employs 0 full-time employees. The company went IPO on 2021-06-30. ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The firm is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The firm is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.
See Also
What is ProKidney Corp's Selling, General & Administrative?
Selling, General & Administrative
-51.8m
USD
Based on the financial report for Dec 31, 2025, ProKidney Corp's Selling, General & Administrative amounts to -51.8m USD.
What is ProKidney Corp's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-54%
Over the last year, the Selling, General & Administrative growth was -2%. The average annual Selling, General & Administrative growth rates for ProKidney Corp have been 10% over the past three years , -54% over the past five years .
